Literature DB >> 15775838

Nocturnal acid breakthrough - approach to management.

Radu Tutuian1, Donald O Castell.   

Abstract

Nocturnal acid breakthrough is defined as the presence of intragastric pH < 4 during the overnight period for at least 60 continuous minutes in patients taking a proton-pump inhibitor (PPI). Nocturnal acid breakthrough occurs in more than 70% of Helicobacter pylori-negative patients on PPI therapy and has clinical consequences in particular in patients with complicated gastroesophageal reflux disease (GERD), Barrett's esophagus, and esophageal motility abnormalities. The clinical importance of nocturnal acid breakthrough and the benefit of adding histamine-2 receptor antagonists (H2RAs) to PPI therapy have been debated ever since these concepts were introduced. In our experience, the addition of bedtime H2RAs is clinically effective in controlling nocturnal acid breakthrough and GERD symptoms.

Entities:  

Mesh:

Year:  2004        PMID: 15775838      PMCID: PMC1480544     

Source DB:  PubMed          Journal:  MedGenMed        ISSN: 1531-0132


  18 in total

1.  Helicobacter pylori eradication increases nocturnal acid breakthrough.

Authors:  M A van Herwaarden; M Samsom; A J Smout
Journal:  Aliment Pharmacol Ther       Date:  2000-07       Impact factor: 8.171

2.  Helicobacter pylori infection influences nocturnal gastric acid breakthrough.

Authors:  T Katsube; K Adachi; A Kawamura; K Amano; Y Uchida; M Watanabe; Y Kinoshita
Journal:  Aliment Pharmacol Ther       Date:  2000-08       Impact factor: 8.171

3.  Bedtime H2 blockers improve nocturnal gastric acid control in GERD patients on proton pump inhibitors.

Authors:  S Xue; P O Katz; P Banerjee; R Tutuian; D O Castell
Journal:  Aliment Pharmacol Ther       Date:  2001-09       Impact factor: 8.171

4.  Bedtime ranitidine does not eliminate the need for a second daily dose of omeprazole to suppress nocturnal gastric pH.

Authors:  R M Khoury; P O Katz; R Hammod; D O Castell
Journal:  Aliment Pharmacol Ther       Date:  1999-05       Impact factor: 8.171

5.  Dose-dependent control of intragastric pH by pantoprazole, 10, 20 or 40 mg, in healthy volunteers.

Authors:  R Tutuian; P O Katz; W Bochenek; D O Castell
Journal:  Aliment Pharmacol Ther       Date:  2002-04       Impact factor: 8.171

Review 6.  The proton-pump inhibitors: similarities and differences.

Authors:  J Horn
Journal:  Clin Ther       Date:  2000-03       Impact factor: 3.393

7.  Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough.

Authors:  William K Fackler; Tina M Ours; Michael F Vaezi; Joel E Richter
Journal:  Gastroenterology       Date:  2002-03       Impact factor: 22.682

8.  Influence of H. pylori infection on meal-stimulated gastric acid secretion and gastroesophageal acid reflux.

Authors:  M Feldman; B Cryer; D Sammer; E Lee; S J Spechler
Journal:  Am J Physiol       Date:  1999-12

9.  Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors.

Authors:  P O Katz; C Anderson; R Khoury; D O Castell
Journal:  Aliment Pharmacol Ther       Date:  1998-12       Impact factor: 8.171

10.  Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure.

Authors:  Tina M Ours; W Keith Fackler; Joel E Richter; Michael F Vaezi
Journal:  Am J Gastroenterol       Date:  2003-03       Impact factor: 10.864

View more
  6 in total

1.  Vacuolar-type H+-ATPase-mediated proton transport in the rat parietal cell.

Authors:  Sascha Kopic; Maximilian E H Wagner; Christoph Griessenauer; Thenral Socrates; Markus Ritter; John P Geibel
Journal:  Pflugers Arch       Date:  2011-11-17       Impact factor: 3.657

Review 2.  Systemic sclerosis: commonly asked questions by rheumatologists.

Authors:  Amber Young; Dinesh Khanna
Journal:  J Clin Rheumatol       Date:  2015-04       Impact factor: 3.517

3.  Secretagogue-dependent and -independent transport of zinc hydration forms in rat parietal cells.

Authors:  Florentina Sophie Ferstl; Alice Miriam Kitay; Rebecca Marion Trattnig; Abrar Alsaihati; John Peter Geibel
Journal:  Pflugers Arch       Date:  2016-10-19       Impact factor: 3.657

4.  Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects.

Authors:  H Jenkins; Y Sakurai; A Nishimura; H Okamoto; M Hibberd; R Jenkins; T Yoneyama; K Ashida; Y Ogama; S Warrington
Journal:  Aliment Pharmacol Ther       Date:  2015-02-23       Impact factor: 8.171

Review 5.  25 Years of Proton Pump Inhibitors: A Comprehensive Review.

Authors:  Daniel S Strand; Daejin Kim; David A Peura
Journal:  Gut Liver       Date:  2017-01-15       Impact factor: 4.519

6.  Night-time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole.

Authors:  Eunsol Yang; Seokuee Kim; Bongtae Kim; Boram Kim; Yechan Kim; Sung Sup Park; Geun Seog Song; Kyung-Sang Yu; In-Jin Jang; SeungHwan Lee
Journal:  Br J Clin Pharmacol       Date:  2022-02-23       Impact factor: 3.716

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.